NEW YORK (Reuters Health) - After approximately 8 years, postmenopausal women with hormone-sensitive breast cancer who received (Arimidex), generically known as anastrazole, had a lower risk of ...
CHICAGO, Dec 14 (Reuters) - Women who took AstraZeneca Plc's breast cancer drug Arimidex fared better than those who took the pill tamoxifen even four years after they stopped taking it, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback